TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2645063

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg b.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29545266

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM) 3.0 pmol/kg/min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA)
Number of subjects: 24
Study: 28978332

Group type: EXPERIMENTAL
Intervention: Polyurethane with absorbent lattice pad dressing (PAL + Tape)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard polyurethane dressing and sutureless securement device (SPU + SSD) (control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (TA + SPU)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination securement-dressing (CSD)
Number of subjects: 124
Study: 26362483

Group type: EXPERIMENTAL
Intervention: Vatreptacog alfa
Number of subjects: 72
Study: 23201624

Group type: EXPERIMENTAL
Intervention: Masai Barefoot Technology shoes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Trainer shoes
Number of subjects: 15
Study: 21640669

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic hysterectomy (MLH)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional laparoscopic hysterectomy (LH)
Number of subjects: 76
Study: 18290855

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 17154704

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting SMART stent
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bare SMART nitinol stent
Number of subjects: 93
Study: 12701975

Group type: EXPERIMENTAL
Intervention: IV ketoprofen (100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 10924815

Group type: EXPERIMENTAL
Intervention: Ischaemic block in Test‐DOMS group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ischaemic block in Ischaemic‐Control group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal‐Control group
Number of subjects: 21
Study: 9295178

Group type: EXPERIMENTAL
Intervention: 0.125 mg Pergolide at bedtime
Number of subjects: 11

Group type: COMPARATOR
Intervention: 250 mg L-Dopa + Carbidopa
Number of subjects: 11
Study: 8437780

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 130
Study: 3080935

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 60 mg/24 h
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31661023

Group type: EXPERIMENTAL
Intervention: Patient advocacy organizations' websites providing information on clinical trials
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patient advocacy organizations' websites providing clinical trial finder or list of relevant trials
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patient advocacy organizations' websites mentioning expanded access (EA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patient advocacy organizations' websites providing specific resources for FDA's EA program
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patient advocacy organizations' websites providing a statement on the federal right to try law
Number of subjects: 118
Study: 28681394

Group type: EXPERIMENTAL
Intervention: Amenamevir 400 mg
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Amenamevir 200 mg
Number of subjects: 751

Group type: COMPARATOR
Intervention: Valaciclovir 1000 mg three times daily (control)
Number of subjects: 751
Study: 25835379

Group type: EXPERIMENTAL
Intervention: TiF4 gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TiF4 gel + CO2 laser
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel + CO2 laser
Number of subjects: 10
Study: 23623905

Group type: EXPERIMENTAL
Intervention: Same-day discharge after PCI
Number of subjects: 12803

Group type: COMPARATOR
Intervention: Routine overnight observation
Number of subjects: 12803

Group type: EXPERIMENTAL
Intervention: Same-day discharge after PCI (observational studies)
Number of subjects: 12803
Study: 21925293

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional axillary dissection
Number of subjects: 100
Study: 19727018

Group type: EXPERIMENTAL
Intervention: Creatine (5 g of Cr + 15 g maltodextrin, 4 times a day for 5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (20 g maltodextrin, 4 times a day for 5 days)
Number of subjects: 16
Study: 18278530

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine treatment
Number of subjects: 17
Study: 12925501

Group type: EXPERIMENTAL
Intervention: Compliance score as a regressor in randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identity link
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonlinear links
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from two randomized trials
Number of subjects: 0
Study: 10774786

Group type: EXPERIMENTAL
Intervention: Molsidomine 12 mg orally for 48 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8850394

Group type: EXPERIMENTAL
Intervention: Active compression-decompression cardiopulmonary resuscitation (ACD CPR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard chest compression according to AHA recommendations
Number of subjects: 56
Study: 1524079

Group type: EXPERIMENTAL
Intervention: Single-lumen catheter
Number of subjects: 91

Group type: COMPARATOR
Intervention: Triple-lumen catheter
Number of subjects: 91
Study: 6402000

Group type: EXPERIMENTAL
Intervention: Dazoxiben 200 mg four times daily
Number of subjects: 20
Study: 4002723

Group type: COMPARATOR
Intervention: Sugar-free tea (0 kcal)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fully adapted formula (518 kcal/dl)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 180
Study: 28674858

Group type: EXPERIMENTAL
Intervention: Self-made cryopreservative fibrin glue (SMC) applied for autograft fixation after pterygium removal.
Number of subjects: 48
Study: 26977079

Group type: EXPERIMENTAL
Intervention: Early developmental intervention (EDI)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 293
Study: 24887794

Group type: EXPERIMENTAL
Intervention: VAC plus ABRA (VAC-ABRA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: VAC alone (control)
Number of subjects: 14
Study: 22545088

Group type: EXPERIMENTAL
Intervention: ziprasidone (40-160 mg/d)
Number of subjects: 73

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study: 20731496

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy for Child Abuse and Neglect (MST‐CAN)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Enhanced Outpatient Treatment (EOT)
Number of subjects: 86
Study: 19301515

Group type: EXPERIMENTAL
Intervention: New dentifrice (Colgate Total Advanced Toothpaste) containing 0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride in a 17% dual silica base
Number of subjects: 233

Group type: COMPARATOR
Intervention: Commercially available fluoride dentifrice (Crest Cavity Protection Toothpaste) containing 0.243% sodium fluoride in a silica base
Number of subjects: 233
Study: 16005497

Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (Basal concentrations)
Number of subjects: 59
Study: 12776900

Group type: EXPERIMENTAL
Intervention: Medical and surgical management options for pain and subfertility
Number of subjects: 0
Study: 11912804

Group type: EXPERIMENTAL
Intervention: Automated telephone disease management (ATDM) calls
Number of subjects: 256
Study: 8818063

Group type: EXPERIMENTAL
Intervention: Intervention school lunches
Number of subjects: 5106

Group type: EXPERIMENTAL
Intervention: Physical education classes
Number of subjects: 5106

Group type: EXPERIMENTAL
Intervention: Self-reported dietary, physical activity, and psychosocial measures
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Physiological measures
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Measurement error for physiologic measures
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Coefficients of variation for lipids, height, and weight
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Intraclass correlations for lipid studies
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Interobserver agreement scores for SOFIT
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Data entry error rates
Number of subjects: 5106
Study: 1427260

Group type: EXPERIMENTAL
Intervention: Experimental group receiving the intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group discussing current news events
Number of subjects: 21
Study: 6330882

Group type: EXPERIMENTAL
Intervention: pivmecillinam
Number of subjects: 30

Group type: COMPARATOR
Intervention: nitrofurantoin
Number of subjects: 30
Study: 30971215

Group type: EXPERIMENTAL
Intervention: Continuing drug treatment with ChEIs (with or without memantine)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Discontinuing drug treatment
Number of subjects: 302
Study: 30077197

Group type: EXPERIMENTAL
Intervention: Oxisperm® test
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HaloSperm G2® DNA fragmentation test
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Logit(p) formula based on HaloSperm G2® results
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall IVF outcome prediction
Number of subjects: 38
Study: 27652698

Group type: EXPERIMENTAL
Intervention: Eugenia uniflora dentifrice
Number of subjects: 50

Group type: COMPARATOR
Intervention: Triclosan-based fluoridated dentifrice (Colgate Total 12)
Number of subjects: 50
Study: 24908241

Group type: EXPERIMENTAL
Intervention: Acupuncture group (scalp acupuncture and electroacupuncture)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 250
Study: 21883424

Group type: EXPERIMENTAL
Intervention: Topical gel with triester glycerol oxide (TGO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical gel without triester glycerol oxide (placebo)
Number of subjects: 50
Study: 20085628

Group type: EXPERIMENTAL
Intervention: Fish oil (50:40:10 mixture of medium-chain fatty acids, soybean oil, and fish oil)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (50:50 mixture of medium-chain fatty acids and soybean oil)
Number of subjects: 25
Study: 17889972

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Unanticipated landings
Number of subjects: 25

Group type: COMPARATOR
Intervention: Anticipated landings
Number of subjects: 25
Study: 15699240

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 14 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (multivitamins plus calcium)
Number of subjects: 56
Study: 12028744

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 136
Study: 10228607

Group type: EXPERIMENTAL
Intervention: Schizandra chinensis and Bryonia alba extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptogens (Schizandra chinensis and Bryonia alba)
Number of subjects: 0
Study: 9057338

Group type: EXPERIMENTAL
Intervention: Dynamic magnetic resonance imaging (MRI) with 10 micrograms intrapenile prostaglandin E1
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Conventional ultrasonography (US)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Spin echo (SE) sequences
Number of subjects: 25
Study: 1853145

Group type: EXPERIMENTAL
Intervention: Nocloprost (100 micrograms/dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin (2.5 g)
Number of subjects: 10
Study: 6348577

Group type: EXPERIMENTAL
Intervention: Preliminary volume expansion, vasodilators, and centrally acting drugs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classical treatment for hypertension with a diuretic
Number of subjects: 30
Study: 31873786

Group type: EXPERIMENTAL
Intervention: prn-IVB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: prn-IVT
Number of subjects: 100
Study: 30897031

Group type: EXPERIMENTAL
Intervention: Hypoxic CHO (HCHO; 6% CHO provided as 2 ml/kg/15 min; FiO2 = 16.3%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypoxic placebo (HPLA; FiO2 = 16.3%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxic placebo (NPLA; FiO2 = 20.9%)
Number of subjects: 10
Study: 28562792

Group type: EXPERIMENTAL
Intervention: Nursing appointments (three appointments alternated bimonthly with two phone calls over five months)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care offered by the Health Unit
Number of subjects: 134
Study: 26376281

Group type: EXPERIMENTAL
Intervention: MUAC < 115 mm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current admission criteria (WHZ < -3 and/or MUAC < 115 mm)
Number of subjects: 0
Study: 23676888

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 141

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 141
Study: 21472441

Group type: EXPERIMENTAL
Intervention: Target guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Path guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistive path guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-guidance (in second experiment)
Number of subjects: 0
Study: 20355225

Group type: COMPARATOR
Intervention: Measurement of insulin-like growth factor-I (IGF-I) and type III pro-collagen (P-III-P) as markers of GH action
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunoassays recognizing different isoforms of pituitary GH
Number of subjects: 0
Study: 17088488

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 200 mg QD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ritonavir (RTV) 100 mg QD
Number of subjects: 36
Study: 14741072

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A as BOTOX)
Number of subjects: 167
Study: 11706485

Group type: EXPERIMENTAL
Intervention: Surgical revision
Number of subjects: 94

Group type: COMPARATOR
Intervention: Expectation (observation)
Number of subjects: 94
Study: 9027267

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 146
Study: 8068051

Group type: EXPERIMENTAL
Intervention: Vegetable protein diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 8
Study: 3318377

Group type: EXPERIMENTAL
Intervention: High-dose carbonyl iron 600 mg three times per day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard ferrous sulfate 60 mg three times per day
Number of subjects: 36
Study: 29967325

Group type: EXPERIMENTAL
Intervention: Breath Concurrence 6 (BC6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary Ectopia (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of BC6 and Deceleration Capacity (DC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PE and Deceleration Capacity (DC)
Number of subjects: 0
Study: 27079740

Group type: EXPERIMENTAL
Intervention: Mizoribine and steroid
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cyclophosphamide and steroid
Number of subjects: 55
Study: 25840742

Group type: EXPERIMENTAL
Intervention: Metoclopramide (dopamine D2-receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23485622

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 6486

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6486
Study: 21276284

Group type: EXPERIMENTAL
Intervention: Rplus
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lplus
Number of subjects: 13

Group type: COMPARATOR
Intervention: Provox Normal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Rplus and Lplus
Number of subjects: 13

Group type: COMPARATOR
Intervention: Stomvent
Number of subjects: 13
Study: 19036851

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (300 microg of selenium a day as high‐selenium yeast for 48 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 17014912

Group type: EXPERIMENTAL
Intervention: Occupational therapy‐led lifestyle treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Routine GP care
Number of subjects: 67
Study: 15482080

Group type: EXPERIMENTAL
Intervention: Day treatment plus abstinent-contingent housing and work (DT+)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Day treatment only (DT)
Number of subjects: 141
Study: 11534312

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngeal mask (LMA)
Number of subjects: 40
Study: 9625308

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg three times daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Interferon-alpha (3 MU three times per week)
Number of subjects: 36
Study: 7574219

Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg/d
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 2168814

Group type: EXPERIMENTAL
Intervention: Qigong and antihypertensive drugs at low dosage
Number of subjects: 61

Group type: COMPARATOR
Intervention: WM group (antihypertensive drugs alone)
Number of subjects: 61
Study: 528285

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intrapleural saline
Number of subjects: 22
Study: 30156030

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 levels in patients with acute influenza
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low CoQ10 levels (<0.5 μg/mL) in patients with acute influenza
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation of CoQ10 levels with inflammatory biomarkers in influenza patients
Number of subjects: 50
Study: 28359749

Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus omega 3 polyunsaturated fatty acids (800 mg DHA and 225 mg EPA daily)
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus placebo
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Omega 3 polyunsaturated fatty acids alone
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1680
Study: 25283851

Group type: EXPERIMENTAL
Intervention: The Original Sound (TOS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Environmental noise
Number of subjects: 34
Study: 25125097

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (Deep NMB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No neuromuscular blockade (No NMB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No NMB
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Deep NMB
Number of subjects: 57
Study: 23565930

Group type: EXPERIMENTAL
Intervention: Prilocaine irrigation (30 mL of 2% prilocaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (prilocaine-free irrigation solution)
Number of subjects: 50
Study: 21718536

Group type: EXPERIMENTAL
Intervention: Random forests classifiers using 160-320 SNPs
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Random forests classifiers using 10 SNPs
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Clinical traits alone
Number of subjects: 417
Study: 18765042

Group type: EXPERIMENTAL
Intervention: Virtual reality training device
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Computer-enhanced training device
Number of subjects: 16
Study: 17169156

Group type: EXPERIMENTAL
Intervention: Men aged > or = 70 years at baseline
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Men who had suffered a stroke
Number of subjects: 2447

Group type: COMPARATOR
Intervention: Men without stroke
Number of subjects: 2447
Study: 14620170

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 56

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 56
Study: 10911005

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continued medical treatment
Number of subjects: 48
Study: 9022529

Group type: EXPERIMENTAL
Intervention: Garlic + Fish Oil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fish Oil
Number of subjects: 50
Study: 7931883

Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 270

Group type: COMPARATOR
Intervention: Conventional phototherapy (daylight fluorescent lamps)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Combination phototherapy
Number of subjects: 270
Study: 3154682

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 18
Study: 30130712

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27770784

Group type: EXPERIMENTAL
Intervention: Biomechanically informed training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Generic training program
Number of subjects: 30
Study: 25743428

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pre-ART
Number of subjects: 96
Study: 23915796

Group type: EXPERIMENTAL
Intervention: Prebiotics (mixture of galacto-oligosaccharide and polydextrose 1:1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 94